MDS’ sites gain Brazilian regulatory certification

By Nick Taylor

- Last updated on GMT

Related tags Mds Mds pharma services Accreditation

MDS Pharma Services has become the first CRO in the UK and second in the US to gain certification from the Brazilian regulatory agency after a “major client” requested it sought accreditation.

Clients using the sites certified by Brazil’s Agencia Nacional de Vigilancia Sanitaria (ANVISA) will have the review of their submissions expedited, helping them get their products to market quicker.

Furthermore, ANVISA only accepts bioavailability/bioequivalence (BA/BE) work that is completely performed at certified sites, Manon Vranderick, vice president for quality and compliance in early stage development, told Outsourcing-Pharma.

Vranderick added that MDS sought ANVISA certification at the request of a major client with products aimed at the Brazilian market. Gaining approval puts MDS among a small group of contract research organisations (CRO) in the US and UK with certification.

ANVISA has accredited MDS’ sites in Belfast, Northern Ireland, making it the only CRO with certification in the UK, and Lincoln, Nebraska, US. This makes MDS only the second CRO to gain ANVISA certification in the US and Vranderick believes this is because of the difficulties it entails.

Vranderick explained that “the certification process is time-consuming, demanding and expensive​”, with MDS spending six months preparing applications that require very detailed information. Following this week long final inspections were conducted at each site.

This commitment was made for a major client that is targeting the Brazilian market, which is projected to be worth more than $18bn (€12.3m) by 2012.

Vranderick added that MDS has the major certifications and will seek accreditation with additional regulatory agencies when it is “necessary to provide a competitive advantage to [its] clients​”.

The ANVISA certification is the second regulatory accreditation MDS’ Belfast site has gained in recent months. In July the site was granted standard and supplementary accreditation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more